AbbVie Inc. filed a current report on November 2, 2026, disclosing that Class II director Jennifer L. Davis notified the Board of her intent to resign effective November 2, 2026, following her appointment as Chief Executive Officer at Align Technology, Inc.

Key Highlights

  • Director resignation: Jennifer L. Davis, a Class II director of AbbVie Inc., notified the Board of her intent to resign on October 28, 2026.
  • Effective date: Her resignation became effective November 2, 2026.
  • Reason stated: The resignation followed her recent appointment as Chief Executive Officer at Align Technology, Inc.
  • No dispute: According to the filing, her resignation "is not the result of any dispute or disagreement with AbbVie on any matter relating to the operations, policies or practices of AbbVie."
  • Exchange listing: AbbVie common stock trades on the New York Stock Exchange under the symbol ABBV (NYSE:ABBV).

AbbVie Board Departure: Davis Steps Down Amid New CEO Role at Align Technology

According to the filing, Jennifer L. Davis informed AbbVie's Board of Directors on October 28, 2026, that she would be stepping down from her position as a Class II director. Her departure took effect on November 2, 2026, the same date the current report was filed with the Securities and Exchange Commission by AbbVie Inc., headquartered at 1 North Waukegan Road, North Chicago, Illinois.

The filing states that Davis's decision to resign was connected to her recent appointment as Chief Executive Officer at Align Technology, Inc. AbbVie explicitly noted in the filing that her resignation "is not the result of any dispute or disagreement with AbbVie on any matter relating to the operations, policies or practices of AbbVie," a standard disclosure required under Item 5.02 of Form 8-K when a director departs.

The report was signed by Perry C. Siatis, Executive Vice President, General Counsel and Secretary of AbbVie Inc., on November 2, 2026. In addition to its common stock (NYSE:ABBV), AbbVie has several senior notes series registered on the New York Stock Exchange, including the 0.750% Senior Notes due 2027 (ABBV27), 2.125% Senior Notes due 2028 (ABBV28), 2.625% Senior Notes due 2028 (ABBV28B), 2.125% Senior Notes due 2029 (ABBV29), and 1.250% Senior Notes due 2031 (ABBV31).

What Was Disclosed

AbbVie disclosed the resignation of Class II director Jennifer L. Davis, effective November 2, 2026, citing her appointment as CEO of Align Technology, Inc. The filing confirmed the departure involved no dispute or disagreement with the company.